Price$48.56-23.63 (-32.73%)
2026-03-042026-06-05
News · 26 weeks84-33%
2025-12-142026-06-07
Mix4190d
- Insider15(37%)
- SEC Filings11(27%)
- Other9(22%)
- Earnings3(7%)
- Analyst3(7%)
Latest news
25 items- INSIDERChairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- ANALYSTBoston Scientific downgraded by Wolfe ResearchWolfe Research downgraded Boston Scientific from Outperform to Peer Perform
- ANALYSTBoston Scientific downgraded by Wells Fargo with a new price targetWells Fargo downgraded Boston Scientific from Overweight to Equal Weight and set a new price target of $55.00
- INSIDERDirector Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form SD filed by Boston Scientific CorporationSD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRFRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpointsLate-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well a
- SECBoston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECBoston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRBoston Scientific enters into $2 billion accelerated share repurchase agreementMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, Boston Scientific will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52
- PRBoston Scientific announces strategic investment in MiRus LLCAgreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloyMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has invested $1.5 billion in return for an approximately 34% equity stake in MiRus LLC, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. As part of the investment agreement, Boston Scientific also received an exclusive option to acqu
- INSIDERDirector Zane Ellen M was granted 3,800 shares, increasing direct ownership by 16% to 27,934 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Weber Christophe Pierre was granted 2,907 shares, increasing direct ownership by 331% to 3,786 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Wichmann David S was granted 3,800 shares, increasing direct ownership by 9% to 45,382 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Cathy R4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Morano Susan E was granted 5,081 shares, increasing direct ownership by 76% to 11,744 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Mega Jessica L was granted 3,800 shares, increasing direct ownership by 46% to 12,035 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by Director Pegus Cheryl4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Habiger David C was granted 3,800 shares, increasing direct ownership by 68% to 9,428 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Ludwig Edward J was granted 3,800 shares, increasing direct ownership by 21% to 21,779 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form S-8 filed by Boston Scientific CorporationS-8 - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific CorporationSCHEDULE 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
- SECBoston Scientific Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- INSIDEREVP, Global Operations O'Connor Padraig Andrew converted options into 1,802 shares and covered exercise/tax liability with 872 shares, increasing direct ownership by 15% to 7,024 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
BSX FAQ
6 questionsWhat does Boston Scientific Corporation do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also...Where does BSX stock trade?
Boston Scientific Corporation (BSX) is listed on NYSE.What sector and industry is BSX in?
Boston Scientific Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about BSX?
Boston Scientific Corporation has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-05-29.What companies are similar to BSX?
Notable peers in the same industry include JNJ (Johnson & Johnson), ABT (Abbott Laboratories), SYK (Stryker Corporation), MDT (Medtronic plc.), BDX (Becton Dickinson and Company). Compare BSX side-by-side with any of them on Quantisnow.How can I track BSX on Quantisnow?
Quantisnow aggregates Boston Scientific Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BSX to receive live email and push alerts on every new disclosure.